Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 15Thoracic 6Gastrointestinal 5Genitourinary 2Other hematologic neoplasm 1Other 1Head & Neck 1CNS 1

Conditions

Brain Neoplasms 1050Glioblastoma 920Glioma 603Central Nervous System Neoplasms 436Astrocytoma 396Gliosarcoma 339Neuroblastoma 325Oligodendroglioma 255Neoplasms 181Medulloblastoma 165Breast Neoplasms 154Sarcoma 114Recurrence 108Ependymoma 105Neoplasm Metastasis 95Meningioma 91Melanoma 88Lymphoma 87Carcinoma, Non-Small-Cell Lung 87Lung Neoplasms 82Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Neurofibromatosis 1 79Wilms Tumor 75Osteosarcoma 69Head and Neck Neoplasms 69Ovarian Neoplasms 68Testicular Neoplasms 67Lymphoma, Non-Hodgkin 67Burkitt Lymphoma 66Familial ependymoma 63

Interventions

Dalteparin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Pulmonary Embolism × CNS × Clear all
NCT00135876 2007-04-27

Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients

Ontario Clinical Oncology Group (OCOG)

Phase 3 Completed
512 enrolled
CNSClassical hematology

Brain Neoplasms, Glioma, Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡